LYNDHURST, N.J., June 7, 2018 /PRNewswire/ -- Amerigen Pharmaceuticals Limited ("Amerigen") today announced the commerciallaunch of its generic bexarotene 75mg capsules following the recent approval of the Company's corresponding Abbreviated New Drug Application ("ANDA") by the U.S. Food and Drug Administration. Amerigen's bexarotene product is a generic equivalent to Valeant
About AmerigenAmerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the U.S. and China. The group is controlled by Amerigen Pharmaceuticals Limited. The U.S. regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province.
The group has products on the market currently in both the U.S. and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the U.S. FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the U.S. FDA.
AMERIGEN: +1 (732) firstname.lastname@example.org www.amerigenpharma.com
View original content:http://www.prnewswire.com/news-releases/amerigen-launches-generic-bexarotene-capsules-300661704.html
SOURCE Amerigen Pharmaceuticals
Subscribe to our Free Newsletters!